{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"description":"Number of patients who relapse within 18 months from autologous stem cell transplantation.","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who have been followed for at least 18 months or have relapsed prior to 18 months post ASCT","reportingStatus":"POSTED","timeFrame":"18 Months","title":"Relapse","type":"SECONDARY","unitOfMeasure":"Participants"}